MARKSANS2025-04-012025-06-30MARKSANS2025-06-30MARKSANS2025-04-012025-06-30in-capmkt:OtherExpenses1MemberMARKSANS2025-04-012025-06-30ItemsThatWillNotBeReclassifiedToProfitAndLoss1MARKSANS2025-04-012025-06-30ItemsThatWillBeReclassifiedToProfitAndLoss1MARKSANS2025-04-012025-06-30AuditorDomain1iso4217:INRiso4217:INRxbrli:shares524404MARKSANSNOTLISTEDINE750C01026Marksans Pharma LimitedMain BoardEquity2025-04-012026-03-312025-08-122025-07-24INRMillionsQuarterlyFirst quarterSingle segmentPharmaceutical Formulation2025-08-1211:45:002025-08-1213:10:00Declaration of unmodified opinion2025-04-012025-06-30UnauditedConsolidated619989000056410000625630000019269400001715470000-102429000098385000060650000231010000159669000054903200007659800000765980000196080000-12120000183960000058202000000005820200006652900001247310000583170000-115000012362000001111000045316000011.291.29001.291.29The consolidated unaudited financial results for the quarter ended 30 June 2025 of Marksans Pharma Limited <BR> ('the Company' or 'the holding company') and its subsidiaries (collectively referred as 'the Group') were <BR> reviewed by the Audit Committee and approved by the Board of Directors at their respective meeting held on 12 <BR> August 2025. The Statutory Auditors of the Company have carried out limited review on the above results in <BR> terms of Regulation 33 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015 ('the <BR> Regulation'), as amended and expressed an unmodified conclusion. <BR> <BR> The consolidated unaudited financial results of the Company have been prepared in accordance with the <BR> recognition and measurement principles laid down in the Indian Accounting Standard 34 ‘Interim Financial <BR> Reporting’, prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued <BR> thereunder and other recognised accounting principles generally accepted in India and in terms of the <BR> Regulation. <BR> <BR> The figures for the quarter ended 31 March 2025 represent the derived figures between the audited figures in <BR> respect of full financial year ended 31 March 2025 and the unaudited published year-to-date figures up to 31 <BR> December 2024, being the date of the end of third quarter of the financial year, which were subjected to a <BR> limited review by the statutory auditor of the Company. <BR> <BR> The Group's activities comprise of manufacturing pharmaceutical formulation and trading in pharmaceutical <BR> products. The Group has only one reportable segment namely 'Pharmaceuticals' as per Ind AS 108 on <BR> 'Operating Segments'. <BR> <BR> Other income, net includes net loss on foreign exchange differences amounting to 37.73 million for the quarter <BR> ended 30 June 2025 31 March 2025 net gain of 25.80 million 30 June 2024: net gain of 26.11 million; year <BR> ended 31 March 2025 net gain of 194.80 million. <BR> <BR> The above consolidated unaudited financials results are available on the Company's website <BR> www.marksanspharma.com and stock exchanges websites , BSE www.bseindia.com and NSE <BR> www.nseindia.com, where the shares of the Company are listed.Other Expenses1596690000Remeasurements of the net defined benefit liabilities/assets-1010000-1010000-250000Foreign currency translation reserve6660500006660500000665290000UnauditedtrueM S K A & Associates true2027-07-31